Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer: The IMPROVE TrialAntonio Avallone, Alfredo Budillon, Francesco Giuliani et al.|Journal of Clinical Oncology|2024Cited by 14
Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left-sided RAS/BRAF wild-type metastatic colorectal cancer: the IMPROVE-2 trialAntonio Avallone, Umberto Malapelle, Giuseppe Santabarbara et al.|Research Square|2025Cited by 0